ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051
active portfolio companies
Investors and Venture Partners spanning Australia, New Zealand, United States and the United Kingdom